Company news
Gyre Therapeutics, Inc. (NASDAQ:GYRE) news
Gyre Therapeutics, Inc. news releases on 6ix. Latest, Oct 14, 2020: Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio…
Press releases — page 3
Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases
October 13, 2020
Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit
September 24, 2020
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
August 5, 2020
Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress
July 12, 2020
Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2020
Catalyst Biosciences Added to Russell 2000 Index
June 28, 2020
Catalyst Biosciences Appoints Charles Democko, Senior Vice President, Regulatory Affairs
June 21, 2020
Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020
June 18, 2020
Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020
June 14, 2020
Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
June 14, 2020
Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference
June 11, 2020
Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
June 9, 2020
Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
June 7, 2020
Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update
May 10, 2020
Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
April 27, 2020
Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
April 20, 2020
Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors
April 5, 2020
Catalyst Biosciences to Present at the Cowen Healthcare Conference
February 23, 2020
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update
February 19, 2020
Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress
February 6, 2020
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress
January 26, 2020
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
January 16, 2020
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
December 18, 2019
Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference
December 8, 2019
Catalyst Biosciences to Present at the Stifel Healthcare Conference
November 11, 2019
Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update
November 6, 2019
Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference
November 5, 2019
Catalyst Biosciences Provides DalcA Phase 2b Trial Update
October 2, 2019